San Diego-based mostly Viking Therapeutics marked alone as a significant competitor in the weight loss drug market in February soon after revealing promising data from the mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when supplied for a weekly injection As well as in March the com